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ABSTRACT:
Epigenetic  silencing  by  promoter  methylation  of  genes  associated  with  cancer 
initiation and progression is a hallmark of tumour cells. As a consequence, testing 
for DNA methylation biomarkers in plasma or other body fluids shows great promise 
for  detection  of  malignancies  at  early  stages  and/or  for  monitoring  response 
to treatment. However, DNA from normal leukocytes may contribute to the DNA 
in plasma and will affect biomarker specificity if there is any methylation in the 
leukocytes. DNA from 48 samples of normal peripheral blood mononuclear cells was 
evaluated for the presence of methylation of a panel of DNA methylation biomarkers 
that have been implicated in cancer. SMART-MSP, a methylation specific PCR (MSP) 
methodology based on real time PCR amplification, high-resolution melting and 
strategic primer design, enabled quantitative detection of low levels of methylated 
DNA. Methylation was observed in all tested mononuclear cell DNA samples for the 
CDH1 and HIC1 promoters and in the majority of DNA samples for the TWIST1 and 
DAPK1 promoters. APC and RARB promoter methylation, at a lower average level, 
was also detected in a substantial proportion of the DNA samples. We found no 
BRCA1, CDKN2A, GSTP1 and RASSF1A promoter methylation in this sample set. 
Several individuals had higher levels of methylation at several loci suggestive of a 
methylator phenotype. In conclusion, methylation of many potential DNA methylation 
biomarkers can be detected in normal peripheral blood mononuclear cells, and is 
likely to affect their specificity for detecting low level disease. However, we found no 
evidence of promoter methylation for other genes indicating that panels of analytically 
sensitive  and  specific  methylation  biomarkers  in  body  fluids  can  be  obtained. 
INTRODUCTION
Recent research has led to the understanding that, 
despite the importance of genetic change, epigenetic 
mechanisms are perhaps the predominant drivers of 
cancer [1-3]. In particular, inactivation of genes by de 
novo promoter methylation accompanied by global 
hypomethylation is the most common DNA lesion of 
cancer cells [2, 3].
The CpG dinucleotide is the principal unit of 
methylation in humans as its palindromic pairing with 
a CpG dinucleotide on the other strand enables the 
semiconservative replication of methylation by DNA 
methyltransferase 1. Regions of high CpG density Oncotarget 2012; 3:  450-461 451 www.impactjournals.com/oncotarget
are referred to as CpG islands. CpG islands are often 
found spanning the promoter and first exon of genes, 
and these promoter region CpG islands are normally 
unmethylated. DNA methylation of promoter regions is 
strongly associated with transcriptional silencing of the 
downstream gene. This may in part be explained by the 
binding of proteins containing methyl binding domains 
which then initiate the formation of complexes that repress 
transcription [4].
De novo methylation of CpG islands is often an early 
event in cancer [5]. Thus aberrant promoter methylation 
of a number of genes shows great promise as biomarkers 
for early cancer detection [5-7]. Ideally methylation 
biomarkers should be detectable in readily accessible 
body fluids or tissues. However, the majority of DNA 
methylation biomarkers lack the sensitivity and specificity 
required for a diagnostic test [7,8]. 
Plasma and serum are the most studied body 
fluids  with  regard  to  DNA  methylation  biomarkers. 
Very sensitive and quantitative methods are needed for 
the  detection  of  these  biomarkers.  However,  tumour-
derived DNA in body fluids may often be significantly 
contaminated with DNA from normal cells especially 
when the tumour is small. Though the source of the 
normal DNA is unclear, it is likely that DNA from normal 
leukocytes may affect biomarker specificity if methylated.
Thus, very sensitive and quantitative methods may be 
needed for the detection of these biomarkers in body 
fluids.
Biomarker  sensitivity  and  specificity  is  also 
influenced  by  the  choice  of  region  for  analysis  and 
the choice of method for methylation analysis. Many 
different methods for the detection of DNA methylation 
are available [9, 10]. The most sensitive methods 
utilise methylation-specific PCR (MSP) [11] in which 
amplification is determined by the methylation of the 
region under the primers. Conventional MSP is widely 
used due to its simplicity. However, it is non-quantitative 
and is also prone to false positive results caused by 
incomplete bisulphite conversion or false priming events 
[5, 9, 12-14]
Thus, when it is necessary to detect rare methylated 
sequences, MSP may be unable to distinguish low-level 
methylation from low-level incomplete conversion 
or false priming. MethyLight, a variant of MSP using 
fluorescent TaqMan probes is more specific [15] as the use 
of the  probe makes it quantitative and enables increased 
specificity. 
We recently developed a highly sensitive probe-
free method called Sensitive Melting Analysis after Real 
Time (SMART)-MSP [12], which can provide quantitative 
data, works well with DNA derived from formalin fixed 
Figure 1: Representative methylation positive samples for CDH1 and TWIST1. Good reproducibility and non-shifted melting 
profiles were observed, and were used as criteria for identification of true positive results for all genes. A. Real time amplification data 
(CDH1). B. High-resolution melting profiles (CDH1). C. Real time amplification data (TWIST1). D. High-resolution melting profiles 
(TWIST1).
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paraffin embedded (FFPE) tissues [16], and is capable 
of identifying many false positives resulting from false 
priming or incomplete conversion of unmethylated 
cytosines during the bisulphite conversion of the DNA 
template. This is possible due to the use of high-resolution 
melting analysis [17], which utilises intercalating dyes that 
can be used at saturating conditions without inhibiting the 
PCR [18]. 
In this contribution, we have evaluated the 
methylation levels in normal peripheral blood mononuclear 
cells for a panel of genes (APC, BRCA1, CDH1, CDKN2A, 
DAPK1, GSTP1, HIC1, RARB, RASSF1A and TWIST1). 
These genes have been implicated as actual or potential 
tumour suppressor genes and are methylated in various 
cancers. These genes have potential as DNA methylation 
biomarkers for both early detection and post-therapeutic 
monitoring.  By  using  SMART-MSP  we  were  able  to 
distinguish artefactual results from true positive results, 
and to obtain quantitative data for the studied panel of 
biomarkers. Thus, we were able to show that some are 
normally methylated at low levels in peripheral blood 
mononuclear cells, whereas methylation was undetectable 
in others. 
RESULTS
Melting profiles of the SMART-MSP assays
The melting profiles of true positives for each assay 
were obtained by amplifying methylated standards. The 
melting temperature (Tm) was 78.3°C for APC, 76.5°C for 
BRCA1, 81.9°C for CDH1, 75.8°C for CDKN2A, 79.5°C 
for DAPK1, 80°C for GSTP1, 79.8°C for HIC1, 81.5°C 
for RARB, 78.2°C for RASSF1A and 79.8°C for TWIST1. 
Only  bands  of  the  expected  size  were  observed  after 
electrophoresis (data not shown).
The sensitivity and quantitative accuracy of the 
SMART-MSP assays
The  sensitivity  of  the  SMART-MSP  assays  was 
tested using a standard dilution series of methylated DNA 
into unmethylated DNA. The CDKN2A and the RASSF1A 
assays were sensitive to 0.1% methylated template with 
high reproducibility. The APC, BRCA1, CDH1, DAPK1, 
GSTP1, HIC1, RARB and TWIST1 assays were sensitive 
to 0.05% methylated template (data not shown). 
All  standards  contained  approximately  equal 
amounts of template suitable for PCR after bisulphite 
Figure 2: Examples of false positive results. False positives caused by incomplete bisulphite conversion were identified as right-
shifted melting profiles (relative to the 100% methylated standard). These were associated with late amplification and poor reproducibility. 
All shown samples would score as positives when using gel electrophoresis. A. The APC SMART-MSP assay. B. The RARB SMART-MSP 
assay. C. The DAPK1 SMART-MSP assay. D. The BRCA1 SMART MSP assay.
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conversion, as evident from the similar CT values obtained 
in the COL2A1 control assay. We used the Rotorgene 
software to obtain a standard curve for the dilution series 
for calculation of the correlation coefficient (r2) and PCR 
efficiency (E) for each assay. The correlation coefficients 
(APC: r2 = 0.987, BRCA1: r2 = 0.985, CDH1: r2 = 0.992, 
CDKN2A: r2 = 0.998, DAPK1: r2 = 0.995, GSTP1: r2 = 
0.985, HIC1: r2 = 0.995, RARB: r2 = 0.982, RASSF1A: 
r2 = 0.978, TWIST1: r2 = 0.995) indicated a strong linear 
relationship between CT values and given concentrations 
for all assays. The PCR efficiency of most assays (APC: E 
= 1.89, CDH1: E = 1.88, CDKN2A E = 1.96, DAPK1: E = 
1.86, GSTP1: E = 1.94, HIC1: E = 1.87, RARB: E = 1.92, 
TWIST1: E = 1.88) was approximately the same as the 
control assay (COL2A1: E =1.90). The PCR efficiencies 
of the BRCA1 (E = 1.78) and RASSF1A (E = 1.98) assays 
were more different from the control assay, but as none of 
the samples were positive for these assays, quantification 
was not necessary. 
Promoter methylation levels in the samples
The COL2A1 control assay was used to normalise 
for DNA input after bisulphite conversion in the real-
time  PCR  quantification  [12].  The  samples  generally 
amplified simultaneously and relatively early with the 
COL2A1  assay.  One  sample  (#45)  that  amplified  late 
for the COL2A1 assay, (indicating a very low number of 
target bisulphite modified templates) was omitted from the 
analysis.
Quantitative data for all samples for each assay is 
shown in Table 2. None of the samples were positive for 
BRCA1, CDKN2A, GSTP1 or RASSF1A methylation in 
the regions analysed. The regions analysed for the other 
genes were detectably methylated in some or all of the 
individuals tested: HIC1: 100%, CDH1: 100%, TWIST1: 
72%, DAPK1: 51%, RARB: 32%, APC: 23%.
Some  regions  tended  to  be  methylated  at  higher 
levels i.e. in a higher proportion of cells than others. The 
estimated methylation levels were highest for the HIC1 
and CDH1 assays. TWIST1, APC, DAPK1 and RARB 
positive samples were methylated at lower levels. The 
mean methylation level of positive samples for each 
gene was: HIC1: 3.61%, CDH1: 1.26%, TWIST1: 0.43%, 
RARB: 0.18%, APC: 0.18%, DAPK1: 0.13%. The overall 
level of methylation observed in the positive samples 
was higher for the assays that were positive in a greater 
proportion of samples. Thus, it is possible that each gene’s 
methylation may represent a continuous variable with the 
more highly methylated genes having the whole range 
above the threshold of detection.
The range of methylation levels varied the most for 
the HIC1 assay (many samples were far from the mean). 
The methylation levels also varied considerably for the 
CDH1 and TWIST1 assays. Real-time amplification data 
and melting profiles for representative samples are shown 
for CDH1 and TWIST1 (Figure 1).
A tendency towards increasing methylation levels 
with increasing age was observed for most of the genes. 
However, more samples would be needed to adequately 
address this question. Two samples (10 and 11) showed 
overall elevated methylation levels for most of the assayed 
genes. These samples were not only methylated at high 
levels but also had a large number of methylated genes. 
In contrast, samples 26, 27, 35, 37, 39, 42, 46, 47 and 48 
overall showed low methylation levels and methylation 
was restricted to a few genes (Table 2).
The reproducibility was not as good for the replicates 
showing the lowest levels of DNA methylation as evident 
from  figure  1A,  and  occasionally  only  one  replicate 
amplified. This can be readily explained by the limiting 
amounts of methylated template at the lowest methylation 
levels. The quantitative data in Table 2 is calculated from 
the mean values of the replicates. In situations where only 
one of the two replicates amplified, the methylation level 
estimated from that replicate was halved. 
Figure  3:  Sequencing  confirms  that  right-shifting 
was due to incomplete conversion. In the APC SMART-
MSP assay seven non-CpG cytosines are found in between the 
primers (shown as upper case T’s when converted during the 
bisulphite modification). The last base of each primer and the 
region in between them are shown here. CpG sites are shown 
in bold. A. Sequencing results for the 100% methylated control. 
All non-CpG cytosines were converted during the bisulphite 
modification. B. Sequencing results for sample 48 from figure 
2A. It is observed that five out of the seven non-CpG cytosines 
found in between the primers were not converted. This is causing 
the right-shift observed in figure 2A.
C  G T  t  T  T T  T  A  t  t  T  T  C
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Identification  of  false  positives  caused  by 
incomplete conversion
In the SMART-MSP assays used, only non-CpG 
cytosines are located between the primers. Thus, if these 
cytosines are not converted to uracil during the bisulphite 
modification, the amplicon will have a higher GC-content, 
melt later, and thus a right-shifting (due to a higher than 
expected melting temperature) of the melting profile will 
be observed. This, in combination with late amplification 
is a strong indicator of a false positive result [12]. 
Occasionally, amplified samples showed markedly 
right-shifted melting profiles, and were scored as false 
positives (Table 2). Examples from the APC, BRCA1, 
DAPK1 and RARB assays are shown in figure 2. Right-
shifting was always associated with late amplification 
and poor reproducibility between replicates as would be 
expected for this type of false positive result [12]. This is 
because incompletely converted molecules are typically 
found at low levels. These samples would have been 
scored as positive results when using gel electrophoresis 
as in conventional MSP because gel electrophoresis sorts 
DNA molecules according to size, and does not evaluate 
the bases found in between the primers as the SMART-
MSP assays do.
Samples were scored as a false positive result in 
situations where both replicates amplified and showed 
right-shifted melting and in situations where only one of 
the replicates amplified and showed a right-shifted melting 
profile while the other replicate did not amplify. Variant 
APC  products  were  sequenced  to  confirm  that  right-
shifting was due to incomplete conversion. An example is 
Table 1: Primer sequences, annealing temperatures, and amplicon information for the SMART-MSP 
assays
Gene
Primer sequences (CpG sites in 
bold and converted Cs as capital 
Ts or As)
Annealing 
temperature 
(°C)
Size 
(bp)
Non-CpG
Cs 
between 
primers
Spanned region (UCSC 
Genome Browser, March 2006: 
NCBI36/hg18)
APC
F-tTcgTtggatgcggaTTagggc
R-ccaatcgAcgAActcccgacg
68 55 7
112101367-112101421
Chr. 5
BRCA1
F-tgTttagcggtagTTTTttggtttTc
R-ttcccgcgcttttccg
65 49 1
38530948-38530996 
Chr. 17
CDH1
F-gtgggcgggTcgtTagTtTc
R-AccacaAccaatcaAcaAcgcgA
65/68 58 3
67328555-67328612
Chr. 16
CDKN2A
F-gTaTTtTTtTcgagTaTtcgTt Tacggc
R-caaatcctctAAaAAAaccgcgA
64 72 6
21964971-21965042 
Chr. 9
DAPK1
F-aggaTagTcggaTcgagTTaacgTc
R-ttAccgaAtcccctccgcgA
67 61 4
89302618-89302678
Chr. 9
GSTP1
F-gcgaTtTcggggaTtTTagggc
R-tAcaccccgAAcgtcgAccg
67 51 5
67107679-67107729 
Chr. 11
HIC1
F-TTaggcggTTagggcgTcgTac
R-ctAcgAAAacacacaccgAccgA
66 54 4
1906662-1906714 
Chr. 17
RARB
F-atgTcgagaacgcgagcgatTc
R-gttccgAatcctaccccgacgA
71 64 3
25444860-25444923 
Chr. 3
RASSF1A
F-cgTTcggTTcgcgTttgTtagc
R-tAAcccgAttAAAcccgtActtcg
68 58 5
50353240-50353297 
Chr. 3
TWIST1
F-cgcggTTaggaTagtTtTTtTcgaTc
R-aAcgcccccgaaccctaAcg
68 59 4
19124102-19124160 
Chr. 7
COL2A1
F-gTaatgTTaggagTaTTTtgtgggTa
R-ctaccccaAAaAaAcccaAtcctA
65 86 1
46667210-46667295 
Chr. 12
It should be noted that optimal annealing temperaturemayvary according to the PCR machine usedand the other parametersof the PCR reaction.Oncotarget 2012; 3:  450-461 455 www.impactjournals.com/oncotarget
shown for sample 48 in figure 3 (also shown in figure 2A). 
It is observed that five out of the seven non-CpG cytosines 
found in between the APC primers were not converted, 
whereas all seven sites were converted in the positive 
control. 
Verification of CDH1 results by MethyLight
The  CDH1 MethyLight assay was quantitatively 
accurate in the range from 100% down to 0.1% methylated 
template. The correlation coefficient of the MethyLight 
assay was: r2 = 0.984, again indicating a strong linear 
relationship between CT values and given concentrations. 
We tested a selection of the samples showing different 
levels of CDH1  methylation  (sample  5,  6,  7,  10,  11, 
13, 14, 19, 20, 36, 41, 43, 44, 46) using MethyLight to 
confirm that these positive results were not a result of 
false priming. In the MethyLight assay, CpG sites are 
also present in the probe sequence which increases the 
specificity for methylated templates. All of the samples, 
except sample 19 which was negative, were shown to be 
methylated at similar but slightly lower levels compared 
to the data obtained by the CDH1 SMART-MSP assay. 
MethyLight amplification data for six of the samples are 
shown in figure 4.
CDH1  SMART-MSP  using  different  annealing 
temperatures
If the observed methylation with the CDH1 assay 
was due to a rare subpopulation of fully methylated cells, 
the samples would be estimated to be methylated at the 
same levels when using a higher annealing temperature. 
We tested a number of the samples showing different 
levels of CDH1 methylation (sample 2, 3, 5, 10, 11, 12, 
15, 18, 20, 37) using 68°C as the annealing temperature 
instead of 65°C. Again, we found high reproducibility and 
non-shifted melting profiles (data not shown). However, 
we found that all samples were methylated at similar but 
slightly lower levels. These results and the MethyLight 
results indicate that there is some heterogeneity in the 
methylation. As the temperature is increased, tolerance of 
the primers binding to an imperfectly matched template is 
decreased.
Confirming  that  CDH1  is  heterogeneously 
methylated by HRM
To further test whether the observed CDH1 
methylation is heterogeneous, we used the same primers 
as for the MethyLight assay, but with the dye SYTO-
9 instead of the probe. This allows evaluation of the 
methylation status of the CpG sites between the primers 
including the two CpG sites covered by the MethyLight 
probe. If left-shifted melting profiles relative to the 100% 
methylated standard are observed this is an indication that 
the two CpG sites are heterogeneously methylated, due to 
a less GC-rich amplicon and/or heteroduplex formation 
Figure 5: Assessment of the methylation status of the two CpG positions found in between the second set of CDH1 
primers by HRM. Left-shifted melting profiles relative to the 100% methylated standards were observed. This is an indication that the 
two CpG sites are not consistently methylated in all of the amplified molecules. A. Amplification data. B. High resolution melting profiles.
B  A 
A 
Figure  4:  Verification  of  CDH1  results  using 
MethyLight. Normalised amplification data for six of the 14 
samples analysed by MethyLight are shown. MethyLight results 
were consistent with the SMART-MSP results. However, sample 
19 did not amplify in the MethyLight assay. This indicates that 
the two additional CpG positions analysed by the MethyLight 
assay are rarely methylated in this sample.Oncotarget 2012; 3:  450-461 456 www.impactjournals.com/oncotarget
Table 2: Summary of the DNA methylation levels estimated by SMART-MSP for each sample ordered 
according to age. 
Sample
(Age/Sex) APC CDH1 DAPK1 HIC1 RARB TWIST1
1 (84/M) 0.09% 0.52% 0.16% 2.72% 0% 0.05%
2 (84/M) 0% 1.68% 0.14% 2.21% 0.06% 0.21%
3 (83/F) 0.06% 1.18% 0.17% 1.46% 0.13% 0.32%
4 (82/M) False positive 0.64% 0.06% 0.96% 0% 0.17%
5 (82/F) 0.24% 1.18% 0.14% 3.13% 0.06% 0.39%
6 (80/F) 0% 3.85% 0.32% 7.69% 0.30% 0.48%
7 (77/M) 0% 3.35% 0.11% 8.25% 0.28% 0.16%
8 (76/M) 0% 0.78% 0% 1.46% 0% 0.17%
9 (75/F) 0% 1.68% 0.18% 12.50% 0% 0.09%
10 (74/M) 0.21% 4.42% 0.39% 12.50% 0.48% 2.06%
11 (71/M) 0.52% 5.83% 0.17% 20.31% 0.45% 7.18%
12 (71/F) 0% 1.79% 0.07% 1.92% 0% 0.07%
13 (71/F) 0% 2.21% 0% 4.74% 0% 0%
14 (69/M) 0% 1.27% 0% 1.92% 0% 0.05%
15 (68/M) 0% 1.27% 0% 14.36% 0.21% 0.42%
16 (68/M) 0,09% 0.73% 0% 3.13% 0.10% 0.15%
17 (66/F) False positive 1.11% False positive 2.06% 0% 0.16%
18 (66/M) 0% 1.18% 0% 5.83% 0.07% 0.24%
19 (61/F) 0% 1.56% 0.09% 1.79% False positive 0.05%
20 (61/F) 0.08% 0.96% 0% 2.92% 0.05% 0.36%
21 (60/M) 0.10% 0,59% 0.05% 2.37% 0.13% 0.05%
22 (58/M) False positive 0.84% 0.06% 1.46% 0% 0%
23 (56/M) 0% 0.45% 0% 0.73% 0% 0.26%
24 (55/M) 0% 0.84% 0.06% 3.35% 0% 0.21%
25 (54/F) 0% 1.03% 0.05% 1.27% 0,06% 0.18%
26 (52/F) 0% 0.36% 0% 1.67% False positive 0%
27 (50/F) False positive 0.48% 0% 1.36% 0% 0.06%
28 (50/M) 0% 1.27% 0.21% 12.50% 0% 0%
29 (49/F) 0% 0.73% 0% 1.46% 0% 0.12%
30 (48/M) 0% 0.28% 0% 4.12% 0% 0%
31 (45/F) 0.26% 2.06% 0.06% 1.67% 0% 0.10%
32 (44/M) 0% 1.92% 0.13% 3.35% 0.16% 0.10%
33 (42/F) 0.06% 1.03% 0.18% 1.10% 0% 0.15%
34 (39/F) 0% 0.36% 0% 1.92% 0% 0.16%
35 (37/M) 0% 0.48% 0% 1.36% 0% 0%
36 (33/M) 0% 1.56% 0% 2.21% 0% 0.11%
37 (33/F) 0% 0.52% 0% 1.27% 0% 0%
38 (33/M) False positive 0.89% 0% 1.56% 0% 0.11%
39 (29/F) 0% 0.28% 0% 1.46% 0% 0%
40 (27/M) 0% 0.52% 0% 2.21% 0% 0%
41 (26/F) 0.09% 1.18% 0.06% 1.67% 0% 0.06%
42 (26/M) 0% 0.45% 0% 0.78% 0% 0.05%
43 (26/F) 0% 0.96% 0.08% 1.18% False positive False positive
44 (25/M) 0% 1.68% 0.13% 2.06% 0.13% 0.10%
45 (23/M) No data No data No data No data No data No data
46 (23/F) 0% 0.36% 0% 0.78% 0% 0%
47 (23/M) 0% 0.63% 0.06% 1.79% 0% False positive
48 (?/?) False positive 0,24% 0% 1,18% False positive 0%Oncotarget 2012; 3:  450-461 457 www.impactjournals.com/oncotarget
[12]. 
We tested a number of the samples (sample 6, 7, 
11, 13, 19, 36, 41, 43, 44, 46) and found broader melting 
profiles extending to the left for some of them (Figure 
5), and some displayed a twin peak. This was interpreted 
as the amplification of molecules having both CpG sites 
methylated as well as molecules having neither or one of 
the two CpG sites between the primers methylated.
DISCUSSION
We found no evidence for methylation of the 
CDKN2A, GSTP1, RASSF1A and BRCA1 promoter regions 
assayed in this set of peripheral blood mononuclear cell 
DNA samples. It is instructive that these biomarkers for 
which we found no methylation have been successfully 
used  in  a  number  of  other  studies.  As  examples, 
methylation of the CDKN2A promoter has been detected 
in sputum of smokers up to 3 years before they were 
diagnosed with cancer [19, 20], GSTP1 has been used 
in prostate cancer detection [21], and RASSF1A can be 
detected in serum from gastric colorectal adenocarcinoma 
patients [22]. Women with detectable BRCA1 methylation 
in the peripheral blood have an increased risk of early 
onset breast cancer [23].
However, we have shown that significant levels of 
mosaic promoter CpG island methylation are present in 
peripheral blood mononuclear cells derived from normal 
individuals for a number of other genes whose methylation 
is implicated in cancer. These results have several 
important implications. 
Firstly,  they  indicate  that  the  assays  that  show 
considerable background methylation will be insufficiently 
specific  for  use  as  DNA  methylation  biomarkers  for 
peripheral blood–based early detection or monitoring. 
Similar  considerations  apply  for  monitoring  of  body 
fluids or tissues that have significant a haematopoietic 
component but these will require further analysis of 
background methylation in other contributing tissues. 
Thus, our results support the use of assays based on 
BRCA1, CDKN2A, GSTP1 and RASSF1A methylation 
as specific biomarkers. However, assays based on APC, 
CDH1, DAPK1, HIC1, RARB and TWIST1 methylation 
may prove to be less specific biomarkers, especially if 
non-quantitative methods are used. 
One reservation about this study using peripheral 
blood mononuclear cells is that the neutrophils which 
comprise the major leukocyte component of blood were 
not  analysed.  Future  studies  will  need  to  investigate 
blood fractions more intensively as well as investigating 
variations in other tissues.
Some  of  the  genes  with  substantial  background 
methylation in this study have been used for DNA 
methylation biomarkers. For example, TWIST1 and RARB 
methylation was used to detect breast cancer cells in ductal 
lavages [24]. Whereas, the assays used were different 
from ours and may have been more specific under the 
reaction conditions used, it is clear that each assay for 
a methylation biomarker needs to be thoroughly tested 
against population controls and appropriate tissues as a 
critical step in its validation. 
Among the panel of genes that we have found to be 
methylated, CDH1 [25] and DAPK1 [26] have previously 
been reported to be methylated in the blood in a high 
proportion of normal individuals. CDH1 was reported 
to be heterogeneously methylated as also found in the 
present study. The use of less sensitive methods and/or 
the use of different blood fractions and a lack of sufficient 
normal controls may explain why the other genes for 
which  we  observed  significant  methylation  have  not 
previously been shown to be methylated in normal blood. 
Furthermore, positives obtained by conventional MSP 
may have been considered as false positive results. In this 
study, false positive results that are likely to be caused 
by  incomplete  conversion  were  readily  identified.  By 
contrast, identification of false positives is not possible 
using conventional MSP. 
The  use  of  a  whole  genome  amplified  (WGA) 
unmethylated control allowed us to determine the 
appropriate PCR conditions for minimising false priming 
events. However, even after optimisation the WGA control 
occasionally amplified. This was associated with a lack of 
reproducibility in the replicates, very late amplification, 
and right-shifted melting profiles. As no CpG sites were 
placed in between most pairs of SMART-MSP primers, 
this allowed us to conclude that the observed right-shifting 
is caused by incomplete conversion of some of the non-
CpG cytosines found between the primers. This was 
verified by sequencing for the APC SMART-MSP assay. 
Similar false positive results likely to be due to the 
amplification of very low-level incompletely converted 
templates were observed in the samples. When these false 
positive reactions were analysed by electrophoresis, a 
fragment of the same size as the 100% methylated positive 
control was observed. These samples would have scored 
as positive by conventional MSP, however, the number 
of non-CpG cytosines between the primers influences the 
likelihood of detecting these false positives. In our BRCA1 
samples, only one non-CpG cytosine is located between 
the primers, due to restrictions in assay design caused by 
the BRCA1 pseudogene[23]. Amplification occurred in 3 
samples and the melting profiles were right-shifted by 0.6-
0.8ºC. Given the size of the amplicon a shift in this range 
is expected for a single C to T change [27,28]. Thus, these 
samples were scored as false positive results. However, for 
the other assays with more non-CpG cytosines between 
the primers, the vast majority of samples we scored as 
false positive results showed much larger right-shifts 
(generally between 1ºC to 4ºC) indicating that several of 
the cytosines were not converted. 
Small right-shifts below 0.6ºC were observed for 
some samples (Figure 1B and D). This was a consequence Oncotarget 2012; 3:  450-461 458 www.impactjournals.com/oncotarget
of the bisulphite conversion procedure being done using 
columns for the standards and using plates for the samples. 
The  precise  kit  used  for  bisulfite  modification  affects 
the melting results probably as a result of different salt 
concentrations  (unpublished  results).  This  correctable 
fault points out the importance of using the exact same 
kit for template production for all high resolution melting 
experiments.
We observed the highest false positive rates in 
the APC and RARB assays. This can be explained by 
the primers for these assays containing fewer non-CpG 
cytosines and thus selecting against incomplete conversion 
less efficiently. For this reason, we recommend designing 
primers containing many non-CpG cytosines and 
preferably right at the 3’ end for at least one of the two 
primers as is the case for our CDH1 primers. 
If primers select strongly against incomplete 
conversion by the inclusion of multiple Ts derived from 
non-CpG Cs (as our CDH1 primers do) and the detected 
methylation levels are relatively high, it may be of interest 
to have CpG positions in between the primers, since this 
allows assessment of whether the methylation between 
the primers is heterogeneous or homogeneous by HRM 
analysis. If a complex melting pattern extending to the 
left is observed this is an indication that the CpG sites in 
between the primers are not consistently methylated. In 
our CDH1 SMART-MSP assay, we have shown that this 
can be assessed by running the assay at different annealing 
temperatures. If methylation levels are estimated to be 
lower when using higher annealing temperatures, this 
indicates that some of the CpG sites under the primers 
are not co-methylated. We interpret our CDH1 results 
as indicating that the CpG site close to the 5’ end of the 
forward primer does not need to be co-methylated when 
using  65ºC  annealing  temperature.  However,  at  68ºC, 
methylation levels were estimated to be slightly lower, 
indicating that this site now needs to be methylated for 
amplification  to  occur.  Thus,  when  heterogeneously 
methylated  DNA  is  analysed  by  quantitative  MSP 
based methods, the estimated methylation levels will be 
dependent on the annealing temperature and the number 
and positions of the CpG sites in the primers. For very 
accurate quantification, methods capable of reading the 
methylation status of individual epialleles, such as digital 
MS-HRM  and  sequencing  [29],  digital  MethyLight 
[30], clonal bisulfite genomic sequencing [31], and next 
generation sequencing of bisulfite modified DNA [32] will 
be necessary [33]. 
Interestingly, the observed individual variation of 
methylation levels for the studied healthy individuals, 
indicates that it may be of interest to further study the 
concept that individual variation in methylation propensity 
can be found in normal peripheral blood mononuclear 
cells. The results indicate that some individuals may 
have a significant burden of epimutations as they have 
increased methylation over a large number of methylatable 
promoter regions. In particular, samples 10 and 11 showed 
higher levels of methylation than the rest of the samples 
and had the most genes methylated as well. By contrast, 
samples 26, 27, 35, 37, 39, 42, 46, 47 and 48 showed low 
methylation levels and the methylation was restricted to 
only a few genes. The reasons for this remain unknown. 
Importantly, our results eliminate the trivial interpretation 
that the apparent hypermethylator phenotype is an artifact 
due to incomplete bisulfite conversion. Defects in methyl 
metabolism remain a possibility [34].
The varying levels of background methylation may 
reflect  cancer  predisposition.  Each  methylated  allele 
represents an epimutation and if such epimutations 
affect genes whose inactivation predisposes to cancer 
development (as is the case for this gene panel), and these 
epimutations also occur in the target tissues for those 
cancers, the risk of developing cancer will be increased 
[34]. Prospective studies will be needed to determine if 
elevated methylation levels in fact predispose to cancer, 
and a larger sample cohort will be needed to address these 
questions appropriately. Interestingly, several studies have 
recently shown that DNA from peripheral blood may be 
differentially methylated between cancer patients and 
normal controls [35-37]. 
In conclusion, because DNA from normal leukocytes 
contributes to the templates prepared from body fluids that 
can be non-invasively used for PCR based analysis [6, 
38], biomarkers methylated in normal blood may be less 
specific, especially when using non-quantitative methods. 
Thus, methylation levels should be assessed quantitatively 
for discrimination of low-level methylation in healthy 
cells from methylated DNA derived from cancer cells. 
MATERIALS AND METHODS
Samples
The investigations were performed after approval 
by the Peter MacCallum Cancer Centre Ethics of Human 
Research committee (Projects 02/70 and 02/26). Peripheral 
blood samples from blood donors were obtained after 
informed consent from the Australian Red Cross Blood 
Service.
DNA extraction and bisulphite modification
Mononuclear cells from 3-5 mL of peripheral 
blood  were  prepared  using  Lymphoprep  (Nyegaard, 
Oslo,  Norway)  and  DNA  was  extracted  using  a 
salting out method [39]. Universal Methylated DNA 
(Chemicon,  Millipore,  Billerica,  MA)  was  used  as  a 
fully  methylated  control.  Whole  genome  amplified 
DNA from peripheral blood cells of normal individuals 
was used as unmethylated DNA as described previously Oncotarget 2012; 3:  450-461 459 www.impactjournals.com/oncotarget
[12]. Standard dilution series of 100%, 10%, 1%, 0.1%, 
0.05% and 0% methylation levels were prepared by 
diluting the fully methylated DNA into unmethylated 
DNA. DNA was quantified with a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, 
DE). 500 ng of genomic DNA or WGA product was 
subjected to bisulphite conversion with the EpiTect® 96 
Bisulphite kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. 
SMART-MSP primer design
The amplicons were designed to allow the HRM 
analysis to assess the conversion status of non-CpG 
cytosines between the primers [12]. The primers overlaid 
a minimum of 2 CpG sites with one of the cytosines of 
a CpG site placed at or adjacent to the 3’ end. Non-CpG 
cytosines were included in the primer sequences to select 
against incompletely converted sequences, and at least one 
of these was placed as close to the 3’ end as possible. The 
primer sequences, genomic regions spanned, amplicon 
sizes and the annealing temperatures are found in Table 
1. The primers for DAPK1 and CDKN2A (p16INK4a) were 
previously published [12].
PCR and HRM conditions for the SMART-MSP 
assays
PCR cycling and HRM analysis were performed 
on the Rotor-Gene 6000™ (Corbett Research, Sydney, 
Australia). SYTO® 9 was used as the intercalating dye 
(Life Technologies, Carlsbad, CA). The reaction mixtures 
consisted of 25 ng of bisulphite modified template (pre 
bisulfite conversion amount), 1x PCR buffer, 2.5 mmol/L 
MgCl2 final (3 mmol/L in the CDH1 assay), 200 nmol/L 
of each primer, 200 µmol/L of each dNTP, 5 µmol/L of 
SYTO 9, 0.5U of HotStarTaq (Qiagen) in a final volume 
of 20 µL. 
The PCR comprised one cycle of 95°C for 15 min, 
followed by 45 cycles of 95°C for 20 s, annealing at the 
appropriate temperature (Table 1) for 30 s, 72°C for 30 
s, and one cycle of 95°C for 1 min. HRM was performed 
from 60°C to 90°C, with a temperature increase at the 
rate of 0.2°C per second for all assays. The annealing 
temperature was experimentally determined for each assay 
to ensure only methylated templates were amplified. For 
each assay, a standard dilution series was run to assess the 
quantitative accuracy and sensitivity. Fully methylated and 
fully unmethylated control (WGA product), unmodified 
control, and no template control were also included in 
every run. All samples were analysed in duplicate.
The CDH1 MethyLight assay
The same forward primer was used for 
the  MethyLight  assay  as  for  the  SMART-
MSP  assay.  The  reverse  primer  sequence  was: 
5’-cgctaattaactaaaaattcacctaccg-3’. The probe sequence 
was FAM-5’-ttcgcgttgttgattgg-3’-BHQ (IDT). The two 
CpG sites between the primers are covered by the probe. 
The reaction mixtures consisted of 25 ng of bisulphite 
modified DNA, 1x PCR buffer, 250 nmol/L of probe, 3 
mmol/L MgCl2, 200 nmol/L of each primer, 200 µmol/L 
of each dNTP, and 0.5U of HotStarTaq (Qiagen) (5U/µL) 
in a total volume of 20 µL. The PCR comprised one cycle 
of 95°C for 15 min, 45 cycles of 95°C for 20 s and 64°C 
for 40 s. PCR was performed on the Rotor-Gene 6000. All 
samples were analysed in duplicate. In some reactions the 
probe was omitted and the primers were used for SMART-
MSP to allow assessment of the methylation status of the 
two CpG sites in the region of the probe by HRM analysis.
Real-Time PCR quantification
The  COL2A1 control assay amplifying a CpG 
free region was used to normalise for DNA input after 
bisulphite conversion in the real-time PCR quantification 
[12]. The relative 2(-delta delta CT) quantification approach [40] 
was used. The CT value of the control COL2A1 assay 
(Table 1) is subtracted from the CT value of the target 
gene  for  the  calibrator  sample  (the  100%  methylated 
standard). For each sample, this value is then subtracted 
from the value resulting from the CT value of the target 
gene minus the CT value for the COL2A1 control assay. 
For this approach to be valid, the amplification efficiencies 
of the target and the control must be approximately equal 
[40]. The take-off values (defined as the cycle at which the 
second derivative is at 20% of the maximum level) given 
by comparative quantification (using the Rotor-Gene 6000 
Series Software, version 1.7.61) were used as CT values in 
the calculations. 
Sequencing
Sequencing  was  used  to  verify  a  higher  melting 
temperature was due to incomplete conversion of some 
of the non-CpG cytosines in between the APC SMART-
MSP primers. For this purpose, a second amplification was 
performed with m13 tagged APC SMART-MSP primers. 
These products were sequenced using BigDye terminator 
chemistry v3.1 on an ABI 3730 (Applied Biosystems).
ACKNOWLEDGEMENTS
This study was supported by grants to AD from the 
Department of Defense Breast Cancer Research Program Oncotarget 2012; 3:  450-461 460 www.impactjournals.com/oncotarget
under award number W81XWH-05-1-0500, the Cancer 
Council of Victoria, the Victorian Cancer Agency and the 
National Breast Cancer Foundation of Australia. Views 
and opinions of, and endorsements by the author(s) do 
not reflect those of the US Army or the Department of 
Defense. We thank Thomas Mikeska and Hongdo Do for 
critical comments on the manuscript.
REFERENCES
1.  Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim 
M, Chin L, Jaenisch R. Reprogramming of a melanoma 
genome by nuclear transplantation. Genes & Development. 
2004; 18:1875-1885. 
2.  Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, 
Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den 
Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota 
M, Imai K, et al. Comparing the DNA hypermethylome 
with gene mutations in human colorectal cancer. PLoS 
Genetics. 2007; 3:1709-1723.
3.  Ushijima  T,  Asada  K.  Aberrant  DNA  methylation  in 
contrast with mutations. Cancer Science. 2010; 101: 300-
305.
4.  Wade PA. Methyl CpG binding proteins: coupling 
chromatin architecture to gene regulation. Oncogene. 2001; 
20:3166-3173.
5.  Laird PW. The power and the promise of DNA methylation 
markers. Nature Reviews Cancer. 2003; 3:253-266.
6.  Shi  H,  Wang  MX,  Caldwell  CW.  CpG  islands:  their 
potential  as  biomarkers  for  cancer.  Expert  Review  of 
Molecular Diagnostics. 2007; 7:519-531.
7.  Cottrell  SE,  Laird  PW.  Sensitive  detection  of  DNA 
methylation.  Annals  of  the  New  York  Academy  of 
Sciences. 2003; 983:120-130.
8.  Mikeska T, Bock C., Do H, Dobrovic A. DNA methylation 
biomarkers in cancer: progress towards clinical 
implementation. Expert Review of Molecular Diagnostics 
(accepted for publication)
9.  Dobrovic  A.  (2005).  Methods  for  Analysis  of  DNA 
Methylation. In: Coleman WB and Tsongalis GJ, eds. 
Molecular diagnostics for the clinical laboratorian (Totowa, 
NJ: Humana Press), pp. 149-160.
10.  Kristensen  LS,  Hansen  LL.  PCR-based  methods  for 
detecting single-locus DNA methylation biomarkers in 
cancer diagnostics, prognostics, and response to treatment. 
Clinical Chemistry. 2009; 55:1471-1483.
11.  Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin 
SB.  Methylation-specific  PCR:  a  novel  PCR  assay  for 
methylation status of CpG islands. Proceedings of the 
National Academy of Sciences of the United States of 
America. 1996; 93:9821-9826.
12.  Kristensen  LS,  Mikeska  T,  Krypuy  M,  Dobrovic  A. 
Sensitive Melting Analysis after Real Time- Methylation 
Specific PCR (SMART-MSP): high-throughput and probe-
free quantitative DNA methylation detection. Nucleic Acids 
Research. 2008; 36:e42.
13.  Rand K, Qu W, Ho T, Clark SJ, Molloy P. Conversion-
specific  detection  of  DNA  methylation  using  real-time 
polymerase chain reaction (ConLight-MSP) to avoid false 
positives. Methods. 2002; 27:114-120.
14.  Shaw RJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou 
T. Methylation enrichment pyrosequencing: combining 
the specificity of MSP with validation by pyrosequencing. 
Nucleic Acids Research. 2006; 34:e78.
15.  Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, 
Shibata D, Danenberg PV, Laird PW. MethyLight: a high-
throughput assay to measure DNA methylation. Nucleic 
Acids Research. 2000; 28:E32.
16.  Kristensen LS, Wojdacz TK, Thestrup BB, Wiuf C, Hager 
H, Hansen LL. Quality assessment of DNA derived from 
up to 30 years old formalin fixed paraffin embedded (FFPE) 
tissue for PCR-based methylation analysis using SMART-
MSP and MS-HRM. BMC Cancer. 2009; 9:453.
17.  Wittwer  CT,  Reed  GH,  Gundry  CN,  Vandersteen  JG, 
Pryor RJ. High-resolution genotyping by amplicon melting 
analysis using LC Green. Clinical Chemistry. 2003; 49:853-
860.
18.  Gudnason H, Dufva M, Bang DD, Wolff A. Comparison 
of multiple DNA dyes for real-time PCR: effects of 
dye concentration and sequence composition on DNA 
amplification  and  melting  temperature.  Nucleic  Acids 
Research. 2007; 35:e127.
19.  Belinsky  SA,  Nikula  KJ,  Palmisano  WA,  Michels  R, 
Saccomanno G, Gabrielson E, Baylin SB, Herman JG. 
Aberrant methylation of p16(INK4a) is an early event in 
lung cancer and a potential biomarker for early diagnosis. 
Proceedings of the National Academy of Sciences of the 
United States of America. 1998; 95:11891-11896.
20.  Palmisano  WA,  Divine  KK,  Saccomanno  G,  Gilliland 
FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung 
cancer by detecting aberrant promoter methylation in 
sputum. Cancer Research. 2000; 60:5954-5958.
21.  Hoque  MO,  Topaloglu  O,  Begum  S,  Henrique  R, 
Rosenbaum E, Van Criekinge W, Westra WH, Sidransky 
D.  Quantitative  methylation-specific  polymerase  chain 
reaction gene patterns in urine sediment distinguish prostate 
cancer patients from control subjects. Journal of Clinical 
Oncology. 2005; 23:6569-6575.
22.  Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li 
GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen 
LB. Detection of RASSF1A promoter hypermethylation in 
serum from gastric and colorectal adenocarcinoma patients. 
World Journal of  Gastroenterol. 2008; 14:3074-3080.
23.  Wong EM, Southey MC, Fox SB, Brown MA, Dowty 
JG,  Jenkins  MA,  Giles  GG,  Hopper  JL,  Dobrovic  A. 
Constitutional methylation of the BRCA1 promoter is 
specifically associated with BRCA1 mutation-associated 
pathology in early-onset breast cancer. Cancer Prev Res Oncotarget 2012; 3:  450-461 461 www.impactjournals.com/oncotarget
(Phila). 2011; 4:23-33.
24.  Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi 
N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson 
NE, Sukumar S. Detection of breast cancer cells in ductal 
lavage fluid by methylation-specific PCR. Lancet. 2001; 
357:1335-1336.
25.  Lombaerts M, Middeldorp JW, van der Weide E, Philippo 
K, van Wezel T, Smit VT, Cornelisse CJ, Cleton-Jansen 
AM.  Infiltrating  leukocytes  confound  the  detection  of 
E-cadherin promoter methylation in tumors. Biochemical 
and Biophysical Research Communications. 2004; 319:697-
704.
26.  Reddy  AN,  Jiang  WW,  Kim  M,  Benoit  N,  Taylor  R, 
Clinger  J,  Sidransky  D,  Califano  JA.  Death-associated 
protein kinase promoter hypermethylation in normal human 
lymphocytes. Cancer Research. 2003; 63:7694-7698.
27.  Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, 
Wittwer C. Genotyping of single-nucleotide polymorphisms 
by high-resolution melting of small amplicons. Clinical 
Chemistry. 2004; 50:1156-1164.
28.  Kristensen LS, Dobrovic A. Direct genotyping of single 
nucleotide polymorphisms in methyl metabolism genes 
using probe-free high-resolution melting analysis. Cancer 
Epidemiology, Biomarkers & Prevention. 2008; 17:1240-
1247.
29.  Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid 
analysis of heterogeneously methylated DNA using digital 
methylation-sensitive high resolution melting: application 
to the CDKN2B (p15) gene. Epigenetics Chromatin. 2008; 
1:7.
30.  Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long 
TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, 
McCormick F, Jones PA, Laird PW. DNA methylation 
analysis by digital bisulfite genomic sequencing and digital 
MethyLight. Nucleic Acids Research. 2008; 36:4689-4698.
31.  Frommer M, McDonald LE, Millar DS, Collis CM, Watt 
F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing 
protocol that yields a positive display of 5-methylcytosine 
residues in individual DNA strands. Proceedings of the 
National Academy of Sciences of the United States of 
America. 1992; 89:1827-1833
32.  Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu 
D, Caldwell CW, Shi H. Ultradeep bisulfite sequencing 
analysis of DNA methylation patterns in multiple gene 
promoters by 454 sequencing. Cancer Research. 2007; 
67:8511-8518.
33.  Mikeska T, Candiloro IL, Dobrovic A. The implications 
of heterogeneous DNA methylation for the accurate 
quantification of methylation. Epigenomics. 2010; 2:561-
573.
34.  Dobrovic A, Kristensen LS. DNA methylation, epimutations 
and cancer predisposition. The International Journal of 
Biochemistry & Cell Biology. 2009; 41:34-39.
35.  Pedersen  KS,  Bamlet  WR,  Oberg  AL,  de  Andrade 
M,  Matsumoto  ME,  Tang  H,  Thibodeau  SN,  Petersen 
GM, Wang L. Leukocyte DNA methylation signature 
differentiates pancreatic cancer patients from healthy 
controls. PLoS One. 2011; 6:e18223.
36.  Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, 
Thibodeau SN, Pankratz VS, Yang P. Methylation markers 
for small cell lung cancer in peripheral blood leukocyte 
DNA. Journal of Thoracic Oncology. 2010; 5:778-785.
37.  Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, 
Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, 
Jacobs IJ, Widschwendter M. An epigenetic signature in 
peripheral blood predicts active ovarian cancer. PLoS One. 
2009; 4:e8274.
38.  Bhatia  K,  Siraj  AK,  Hussain  A,  Bu  R,  Gutierrez  MI. 
The tumor suppressor gene 14-3-3 sigma is commonly 
methylated in normal and malignant lymphoid cells. Cancer 
Epidemiology, Biomarkers & Prevention. 2003; 12:165-
169.
39.  Miller SA, Dykes DD, Polesky HF. A simple salting out 
procedure for extracting DNA from human nucleated cells. 
Nucleic Acids Research. 1988; 16(3):1215.
40.  Livak  KJ,  Schmittgen  TD.  Analysis  of  relative  gene 
expression data using real-time quantitative PCR and the 
2(-Delta Delta C(T)) method. Methods. 2001; 25:402-408.